Search results
Showing 61 to 75 of 201 results for advanced breast cancer
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Awaiting development Reference number: GID-TA11489 Expected publication date: TBC
Awaiting development Reference number: GID-TA10960 Expected publication date: TBC
Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults.
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Microwave ablation for primary or metastatic cancer in the lung (HTG609)
Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).
View recommendations for HTG609Show all sections
Effectivness of 26 Gy in 5 fractions over 1 week regimen in people receiving breast construction- What is the effectiveness of...
Awaiting development Reference number: GID-TA11769 Expected publication date: TBC
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (HTG642)
Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.
Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause (TA1143)
Evidence-based recommendations on fezolinetant (Veoza) for treating moderate to severe vasomotor symptoms associated with menopause.
Show all sections
in 15 fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are also...
Awaiting development Reference number: GID-TA11487 Expected publication date: 27 May 2027